Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 17/20 | 0.79 |
| ▸ | AVPR1A | P37288 | 16/20 | 0.60 |
| ▸ | OXTR | P30559 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8407921 | 0.82 | AVPR2 (0.77) | AVPR2AVPR1AOXTR | |
| SCHEMBL9060789 | 0.82 | AVPR2 (0.53) | AVPR2AVPR1A | |
| SCHEMBL8406431 | 0.82 | AVPR2 (0.63) | AVPR2AVPR1AOXTR | |
| SCHEMBL8820686 | 0.79 | AVPR2 (0.82) | AVPR2AVPR1AOXTR | |
| SCHEMBL5239153 | 0.77 | AVPR2 (0.45) | AVPR2AVPR1AOXTR | |
| SCHEMBL9060382 | 0.77 | AVPR2 (0.49) | AVPR2AVPR1A | |
| SCHEMBL8819700 | 0.77 | AVPR2 (0.69) | AVPR2AVPR1AOXTR | |
| SCHEMBL8819604 | 0.76 | AVPR2 (0.78) | AVPR2AVPR1AOXTR | |
| SCHEMBL7342127 | 0.76 | AVPR2 (0.77) | AVPR2AVPR1AOXTR | |
| SCHEMBL8797804 | 0.76 | AVPR1A (1.00) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | claimed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |